Incyte gets global rights to anti-PD1 mAb from MacroGenics
MacroGenics Inc. granted Incyte Corp. exclusive global rights to its anti-PD1 monoclonal antibody candidate MGA012, which is in Phase I trials for solid tumors.
- Large Molecule
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com